Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Normal liver stiffness and influencing factors in healthy children: An individual participant data meta‐analysis
Li, Darrick K. , Khan, Muhammad Rehan , Chongsrisawat, Voranush , Swangsak, Panida, Teufel‐Schäfer, Ulrike , Engelmann, Guido, Goldschmidt, Imeke , Baumann, Ulrich , Tokuhara, Daisuke , Cho, Yuki , Ramm, Grant A. , Lewindon, Peter , Cassiman, David , Ciucă, Ioana Mihaiela , Prokop, Larry, Haffar, Samir , Furuya, Katryn N. , Prokop, Larry D, Bazerbachi, F , Wang, Zhen , Rowland, Marion , Mjelle, Anders Batman , Witters, Peter , Corey, Kathleen E. , Murad, M. Hassan , Bazerbachi, Fateh

Mayo Clinic

Liver International | September 28, 2020 | Volume: 40 | Issue: 11 | Pages: 2602-2611

10.1111/liv.14658 | PMID 32901449 Get It

AbstractBackground & AimsAlthough transient elastography (TE) is used to determine liver stiffness as a surrogate to hepatic fibrosis, the normal range in children is not well defined. We performed a systematic review and individual participant data (IPD) meta‐analysis to determine the range of liver stiffness in healthy children and evaluate the influence of important biological parameters.MethodsWe pooled data from 10 studies that examined healthy children using TE. We divided 1702 children into two groups: ≥3 years (older group) and < 3 years of age (younger group). Univariate and multivariate linear regression models predicting liver stiffness were conducted.ResultsAfter excluding children with obesity, diabetes, or abnormal liver tests, 652 children were analysed. Among older children, mean liver stiffness was 4.45 kPa (95% confidence interval 4.34‐4.56), and increased liver stiffness was associated with age, sedation status, and S probe use. In the younger group, the mean liver stiffness was 4.79 kPa (95% confidence interval 4.46‐5.12), and increased liver stiffness was associated with sedation status and Caucasian race. In a subgroup analysis, hepatic steatosis on ultrasound was significantly associated with increased liver stiffness. We define a reference range for normal liver stiffness in healthy children as 2.45‐5.56 kPa.ConclusionsWe have established TE‐derived liver stiffness ranges for healthy children and propose an upper limit of liver stiffness in healthy children to be 5.56 kPa. We have identified increasing age, use of sedation, probe size, and presence of steatosis on ultrasound as factors that can significantly increase liver stiffness.
TRIM28 regulates sprouting angiogenesis through VEGFR‐DLL4‐Notch signaling circuit
Wang, Yinfang, Wang, Yinfang, Singh, Angom Ramcharan, Zhao, Yuanyuan , Du, Tao , Wan, Xiaohong, Wang, Nanping , Wang, Ying, Zhang, Peng , Wang, Ying , Wang, Ying , Wang, Yinfang, Wang, Yinfang, Huang, Yitong Pepper , Mukhopadhyay, Debabrata , Wang, Ying

Mayo Clinic

The FASEB Journal | September 28, 2020 | Volume: 34 | Issue: 11 | Pages: 14710-14724

10.1096/fj.202000186rrr | PMID 32918765 Get It

Abstract Sprouting angiogenesis is a highly coordinately process controlled by vascular endothelial growth factor receptor (VEGFR)‐Notch signaling. Here we investigated whether Tripartite motif‐containing 28 (TRIM28), which is an epigenetic modifier implicated in gene transcription and cell differentiation, is essential to mediate sprouting angiogenesis. We observed that knockdown of TRIM28 ortholog in zebrafish resulted in developmental vascular defect with disorganized and reduced vasculatures. Consistently, TRIM28 knockdown inhibited angiogenic sprouting of cultured endothelial cells (ECs), which exhibited increased mRNA levels of VEGFR1, Delta‐like (DLL) 3, and Notch2 but reduced levels of VEGFR2, DLL1, DLL4, Notch1, Notch3, and Notch4.The regulative effects of TRIM28 on these angiogenic factors were partially mediated by hypoxia‐inducible factor 1 α (HIF‐1α) and recombination signal‐binding protein for immunoglobulin kappa J region (RBPJκ). In vitro DNA‐binding assay showed that TRIM28 knockdown increased the association of RBPJκ with DNA sequences containing HIF‐1α‐binding sites. Moreover, the phosphorylation of TRIM28 was controlled by VEGF and Notch1 through a mechanism involving RBPJκ‐dual‐specificity phosphatase (DUSP)‐p38 MAPK, indicating a negative feedback mechanism. These findings established TRIM28 as a crucial regulator of VEGFR‐Notch signaling circuit through HIF‐1α and RBPJκ in EC sprouting angiogenesis.
Gradient-Based Rapid Digital Immunoassay for High-Sensitivity Cardiac Troponin T (hs-cTnT) Detection in 1 μL Plasma
Jing, Wenwen , Wang, Yi , Zhang, Fenni , Yang, Yunze , Ma, Guangzhong , Snozek, Christine, Tao, Nongjian , Chen, C.-H. , Zhang, Fenni , Ma, Guangzhong , Snozek, Christine L N, Wang, Shaopeng , Chen, Chao , Jing, Wenwen , Chen, Chao , Yang, Eric H. , Wang, Shaopeng

Mayo Clinic

ACS Sensors | September 28, 2020 | Volume: 6 | Issue: 2 | Pages: 399-407

10.1021/acssensors.0c01681 | PMID 32985183 Get It

Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition
Ramanan, Vijay K. , Wang, Xuewei , Przybelski, Scott A. , Raghavan, Sheelakumari , Batzler, Anthony , Kosel, Matthew , Hohman, Timothy J. , Graff‐Radford, Jonathan , Lowe, Val J. , Petersen, Ronald C. , Ross, Owen A. , Vemuri, Prashanthi , Graff-Radford, Jonathan , Mielke, Michelle M , Seto, Mabel , Vemuri, Prashanthi , Ross, Owen A , Ramanan, Vijay K , Heckman, Michael G. , Knopman, David S. , Mielke, Michelle M. , Jack, Clifford R.

Mayo Clinic

Brain Communications | September 26, 2020 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaa159 | PMID 33426524 Get It

AbstractTau deposition is a key biological feature of Alzheimer’s disease that is closely related to cognitive impairment. However, it remains poorly understood why certain individuals may be more susceptible to tau deposition while others are more resistant. The recent availability of in vivo assessment of tau burden through positron emission tomography provides an opportunity to test the hypothesis that common genetic variants may influence tau deposition. We performed a genome-wide association study of tau-positron emission tomography on a sample of 754 individuals over age 50 (mean age 72.4 years, 54.6% men, 87.6% cognitively unimpaired) from the population-based Mayo Clinic Study of Aging. Linear regression was performed to test nucleotide polymorphism associations with AV-1451 (18F-flortaucipir) tau-positron emission tomography burden in an Alzheimer’s-signature composite region of interest, using an additive genetic model and covarying for age, sex and genetic principal components. Genome-wide significant associations with higher tau were identified for rs76752255 (P = 9.91 × 10−9, β = 0.20) in the tau phosphorylation regulatory gene PPP2R2B (protein phosphatase 2 regulatory subunit B) and for rs117402302 (P = 4.00 × 10−8, β = 0.19) near IGF2BP3 (insulin-like growth factor 2 mRNA-binding protein 3). The PPP2R2B association remained genome-wide significant after additionally covarying for global amyloid burden and cerebrovascular disease risk, while the IGF2BP3 association was partially attenuated after accounting for amyloid load. In addition to these discoveries, three single nucleotide polymorphisms within MAPT (microtubule-associated protein tau) displayed nominal associations with tau-positron emission tomography burden, and the association of the APOE (apolipoprotein E) ɛ4 allele with tau-positron emission tomography was marginally nonsignificant (P = 0.06, β = 0.07). No associations with tau-positron emission tomography burden were identified for other single nucleotide polymorphisms associated with Alzheimer’s disease clinical diagnosis in prior large case–control studies. Our findings nominate PPP2R2B and IGF2BP3 as novel potential influences on tau pathology which warrant further functional characterization. Our data are also supportive of previous literature on the associations of MAPT genetic variation with tau, and more broadly supports the inference that tau accumulation may have a genetic architecture distinct from known Alzheimer’s susceptibility genes, which may have implications for improved risk stratification and therapeutic targeting.
Data‐driven discovery of probable Alzheimer's disease and related dementia subphenotypes using electronic health records
Xu, Jie , Xu, Zhenxing , Adekkanattu, Prakash , Brandt, Pascal , Jiang, Guoqian , Kiefer, Richard C. , Luo, Yuan , Mao, Chengsheng , Zhang, Yiye , Isaacson, Richard , Pathak, Jyotishman , Brandt, Pascal S , Xu, Jie , Luo, Yuan , Wang, Fei “Fred” , Pacheco, Jennifer A. , Rasmussen, Luke V.

Mayo Clinic

Learning Health Systems | September 24, 2020 | Volume: 4 | Issue: 4 | Pages: No page available

10.1002/lrh2.10246 | PMID 33083543 Get It

AbstractIntroductionWe sought to assess longitudinal electronic health records (EHRs) using machine learning (ML) methods to computationally derive probable Alzheimer's Disease (AD) and related dementia subphenotypes.MethodsA retrospective analysis of EHR data from a cohort of 7587 patients seen at a large, multi‐specialty urban academic medical center in New York was conducted. Subphenotypes were derived using hierarchical clustering from 792 probable AD patients (cases) who had received at least one diagnosis of AD using their clinical data. The other 6795 patients, labeled as controls, were matched on age and gender with the cases and randomly selected in the ratio of 9:1. Prediction models with multiple ML algorithms were trained on this cohort using 5‐fold cross‐validation. XGBoost was used to rank the variable importance.ResultsFour subphenotypes were computationally derived. Subphenotype A (n = 273; 28.2%) had more patients with cardiovascular diseases; subphenotype B (n = 221; 27.9%) had more patients with mental health illnesses, such as depression and anxiety; patients in subphenotype C (n = 183; 23.1%) were overall older (mean (SD) age, 79.5 (5.4) years) and had the most comorbidities including diabetes, cardiovascular diseases, and mental health disorders; and subphenotype D (n = 115; 14.5%) included patients who took anti‐dementia drugs and had sensory problems, such as deafness and hearing impairment.The 0‐year prediction model for AD risk achieved an area under the receiver operating curve (AUC) of 0.764 (SD: 0.02); the 6‐month model, 0.751 (SD: 0.02); the 1‐year model, 0.752 (SD: 0.02); the 2‐year model, 0.749 (SD: 0.03); and the 3‐year model, 0.735 (SD: 0.03), respectively. Based on variable importance, the top‐ranked comorbidities included depression, stroke/transient ischemic attack, hypertension, anxiety, mobility impairments, and atrial fibrillation. The top‐ranked medications included anti‐dementia drugs, antipsychotics, antiepileptics, and antidepressants.ConclusionsFour subphenotypes were computationally derived that correlated with cardiovascular diseases and mental health illnesses. ML algorithms based on patient demographics, diagnosis, and treatment demonstrated promising results in predicting the risk of developing AD at different time points across an individual's lifespan.
Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk
Ghoneim, Dalia, Zhu, Jingjing , Murff, Harvey J. , Ye, Fei , Khankari, Nikhil K. , Haycock, Philip , Antwi, Samuel O. , Yang, Yaohua , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Rabe, Kari G. , Duggal, Priya , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hassan, Manal M. , Helzlsouer, Kathy J. , Holly, Elizabeth A. , Hoover, Robert N. , Katske, Verena, Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Oberg, Ann L. , Porta, Miquel , Rothman, Nathaniel , Sesso, Howard D. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Wolpin, Brian M. , Jacobs, Eric J. , Petersen, Gloria M. , Stolzenberg-Solomon, Rachel Z., Wu, Lang , Haycock, Philip , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Visvanathan, Kala , Bamlet, William R , Brennan, Paul , Chaffee, Kari G. , Hackert, Thilo , Katzke, Verena , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Sesso, Howard D , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Klein, Alison P , Antwi, Samuel O , Murphy, Neil , Porta, Miquel , Duggal, Priya , Zheng, Wei , Long, Jirong , Setiawan, Veronica Wendy , Wilkens, Lynne R. , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , White, Emily , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Brais, Lauren K , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Rothman, Nathaniel , Silverman, Debra T. , Thompson, Ian M. , Wang, Xiaoliang , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Duell, Eric J. , Risch, Harvey A. , Ámundadóttir, Laufey T. , Kraft, Peter , Klein, Alison P. , Shu, Xiao‐Ou , Yang, Yaohua

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 23, 2020 | Volume: 29 | Issue: 12 | Pages: 2735-2739

10.1158/1055-9965.epi-20-0651 | PMID 32967863 Get It

Abstract Background: Whether circulating polyunsaturated fatty acid (PUFA) levels are associated with pancreatic cancer risk is uncertain. Mendelian randomization (MR) represents a study design using genetic instruments to better characterize the relationship between exposure and outcome. Methods: We utilized data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case–Control Consortium, involving approximately 9,269 cases and 12,530 controls of European descent, to evaluate associations between pancreatic cancer risk and genetically predicted plasma n-6 PUFA levels. Conventional MR analyses were performed using individual-level and summary-level data. Results: Using genetic instruments, we did not find evidence of associations between genetically predicted plasma n-6 PUFA levels and pancreatic cancer risk [estimates per one SD increase in each PUFA-specific weighted genetic score using summary statistics: linoleic acid odds ratio (OR) = 1.00, 95% confidence interval (CI) = 0.98–1.02; arachidonic acid OR = 1.00, 95% CI = 0.99–1.01; and dihomo-gamma-linolenic acid OR = 0.95, 95% CI = 0.87–1.02]. The OR estimates remained virtually unchanged after adjustment for covariates, using individual-level data or summary statistics, or stratification by age and sex. Conclusions: Our results suggest that variations of genetically determined plasma n-6 PUFA levels are not associated with pancreatic cancer risk. Impact: These results suggest that modifying n-6 PUFA levels through food sources or supplementation may not influence risk of pancreatic cancer.
Addressing the Challenges of Eosinophilia and Mastocytosis
Craig, Fiona E. , Reichard, Kaaren K. , Kelemen, Katalin, Horny, Hans-Peter, Wang, Sa A. , King, Rebecca L. , Rimsza, Lisa, Rimsza, Lisa M. , George, Tracy I. , Orazi, Attilio , Quintanilla‐Martínez, Leticia

Mayo Clinic

American Journal of Clinical Pathology | September 22, 2020 | Volume: 155 | Issue: 2 | Pages: 156-159

10.1093/ajcp/aqaa206 | PMID 33367532 Get It

Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
Hampel, Paul J. , Call, Timothy G. , Rabe, Kari G. , Leis, José F., Koehler, Amber B. , Fonder, Amie , Schwager, Susan M., Dyke, Daniel L. Van , Braggio, Esteban , Kenderian, Saad S. , Fonder, Amie L, Van Dyke, Daniel L, Chaffee, Kari G. , Braggio, Esteban , Ding, Wei , Muchtar, Eli , Wang, Yucai , Witzig, Thomas E. , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

The Oncologist | September 21, 2020 | Volume: 25 | Issue: 11 | Pages: 974-980

10.1634/theoncologist.2020-0388 | PMID 32886416 Get It

Abstract Background Approximately 25% of patients with chronic lymphocytic leukemia (CLL) experience a flare of disease following ibrutinib discontinuation. A critical question is whether this phenomenon may also occur when ibrutinib is temporarily held. This study aimed to determine the frequency and characteristics of disease flares in this setting and assess risk factors and clinical outcomes. Materials and Methods We identified all patients with CLL seen at Mayo Clinic between October 2012 and March 2019 who received ibrutinib. Temporary interruptions in treatment and associated clinical findings were ascertained. Results Among the 372 patients identified, 143 (38%) had at least one temporary interruption (median 1 hold, range 1–7 holds) in treatment. The median duration of interruption was 8 days (range 1–59 days) and the most common indication was periprocedural. Among the 143 patients with ≥1 hold, an associated disease flare was seen in 35 (25%) patients: mild (constitutional symptoms only) in 21 patients and severe (constitutional symptoms with exam/radiographic findings or laboratory changes) in 14 patients. Disease flare resolved with resuming ibrutinib in all patients. Predictive factors of disease flare included progressive disease at time of hold and ≥ 24 months of ibrutinib exposure. The occurrence of disease flare with an ibrutinib hold was associated with shorter event-free survival (hazard ratio 2.3; 95% confidence interval 1.3–4.1; p = .007) but not overall survival. Conclusion Temporary interruptions in ibrutinib treatment of patients with CLL are common, and one quarter of patients who held ibrutinib in this study experienced a disease flare. Resolution with resuming ibrutinib underscores the importance of awareness of this phenomenon for optimal management. Implications for Practice Ibrutinib is a very effective treatment for chronic lymphocytic leukemia (CLL) but needs to be taken continuously. Side effects, such as increased bleeding risk with procedures, require temporary interruptions in this continuous treatment. Rapid CLL progression following ibrutinib discontinuation has been increasingly recognized. This study demonstrates that similar flares in disease signs or symptoms may occur during ibrutinib holds as well. Importantly, management with restarting ibrutinib led to quick clinical improvement. Awareness of this phenomenon among clinicians is critical to avoid associated patient morbidity and premature cessation of effective treatment with ibrutinib if the flare is misidentified as true progression of disease.
Midterm results of different treatment methods for myocardial bridging in patients after septal myectomy
Wang, Shengwei , Wang, Shuiyun, Wang, Shuiyun, Lai, Yongqiang, Song, Changpeng , Cui, Hao, Meng, Liukun, Zhu, Changsheng, Wu, Rong , Huang, Xiaohong , Wang, Shuiyun , Wang, Shuiyun , Lai, Yongqiang , Zhu, Changsheng

Mayo Clinic

No container title available | September 21, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.160071231.11865748 Get It

Background: Myocardial bridging (MB) is commonly treated in patients with hypertrophic cardiomyopathy (HCM). However, whether and how MB should be treated in patients with hypertrophic obstructive cardiomyopathy (HOCM) who underwent septal myectomy remain unclear. Methods: A total of 823 adults with HOCM who underwent septal myectomy at the Fuwai Hospital from 2011 to 2017 were retrospectively studied. Results: Overall, 31 events occurred: 24 patients died and 7 had nonfatal myocardial infarction (MI). The 3-year cumulative event-free survival of all-cause death (97.9% vs 100% vs 100% vs 98.4%, p=0.89) and cardiovascular death (98.3% vs 100% vs 100% vs 98.4%, p=0.63) were similar among the four groups (non-MB, CABG, unroofing, untreated, respectively). The 3-year cumulative event-free survival of nonfatal MI (100% vs 97.5% vs 98.0% vs 89.9%, p<0.001) and combined endpoints (97.9% vs 97.5% vs 98.0% vs 88.4%, p=0.02) were significantly lowest in untreated MB. Cox regression analysis indicated that untreated MB was a significant independent predictor of combined endpoints (hazard ratio [HR]: 4.06, 95% confidence interval [CI]: 1.60–10.32, p<0.001). Moreover, 49 patients underwent coronary artery computed tomography after surgery. The patency rate of the saphenous vein graft (SVG) was significantly higher than that of the left internal mammary artery (LIMA) (13.3% vs 84.2%, p<0.001). No MB was detected in the unroofing group. Conclusions: Surgical MB treatment could be beneficial and performed safely during septal myectomy. Myocardial unroofing is the recommended treatment for MB, and unroofing when technically possible may be preferable for long-term outcomes.
Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis
Nayfeh, Tarek , Alzuabi, Muayad , Kuchkuntla, Aravind Reddy, Newman, Connie B. , Murad, M. Hassan , Rajjo, Tamim , Hasan, Bashar , Murad, Mohammad Hassan, Rajjo, Tamim I, Murad, M Hassan , Nayfeh, Tarek , Hasan, Bashar , Wang, Zhen , Prokop, Larry J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 21, 2020 | Volume: 105 | Issue: 12 | Pages: 3695-3703

10.1210/clinem/dgaa673 | PMID 32954416 Get It

Abstract Background Excess adipose tissue is associated with an abnormal lipid profile that may improve with weight reduction. In this meta-analysis, we aimed to estimate the magnitude of change in lipid parameters associated with weight loss in adults who are overweight or obese. Methods We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Scopus from 2013 to September, 2018. We included randomized controlled trials (RCTs) that evaluated interventions to treat adult obesity (lifestyle, pharmacologic and surgical) with follow-up of 6 months or more. Results We included 73 RCTs with moderate-to-low risk of bias, enrolling 32 496 patients (mean age, 48.1 years; weight, 101.6 kg; and body mass index [BMI], 36.3 kg/m2). Lifestyle interventions (diet, exercise, or both), pharmacotherapy, and bariatric surgery were associated with reduced triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) concentrations and increased high-density lipoprotein cholesterol (HDL-C) at 6 and 12 months. The following data are for changes in lipid parameters after 12 months of the intervention with 95% CI. Following lifestyle interventions, per 1 kg of weight lost, TGs were reduced by –4.0 mg/dL (95% CI, –5.24 to –2.77 mg/dL), LDL-C was reduced by –1.28 mg/dL (95% CI, –2.19 to –0.37 mg/dL), and HDL-C increased by 0.46 mg/dL (95% CI, 0.20 to 0.71 mg/dL). Following pharmacologic interventions, per 1 kg of weight lost, TGs were reduced by –1.25 mg/dL (95% CI, –2.94 to 0.43 mg/dL), LDL-C was reduced by –1.67 mg/dL (95% CI, –2.28 to –1.06 mg/dL), and HDL-C increased by 0.37 mg/dL (95% CI, 0.23 to 0.52 mg/dL). Following bariatric surgery, per 1 kg of weight lost, TGs were reduced by –2.47 mg/dL (95% CI, –3.14 to –1.80 mg/dL), LDL-C was reduced by –0.33 mg/dL (95% CI, –0.77 to 0.10 mg/dL), and HDL-C increased by 0.42 mg/dL (95% CI, 0.37 to 0.47 mg/dL). Low-carbohydrate diets resulted in reductions in TGs and increases in HDL-C, whereas low-fat diets resulted in reductions in TGs and LDL-C and increases in HDL-C. Results were consistent across malabsorptive and restrictive surgery. Conclusions Weight loss in adults is associated with statistically significant changes in serum lipids. The reported magnitude of improvement can help in setting expectations, inform shared decision making, and facilitate counseling.